Characterising the RNA-binding protein atlas of the mammalian brain uncovers RBM5 misregulation in mouse models of Huntington's disease

Mullari, Meeli; Fossat, Nicolas; Skotte, Niels H; Asenjo-Martinez, Andrea; Humphreys, David T; Bukh, Jens; Kirkeby, Agnete; Scheel, Troels K H; Nielsen, Michael L

Published in:
Nature Communications

DOI:
10.1038/s41467-023-39936-x

Publication date:
2023

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
https://doi.org/10.1038/s41467-023-39936-x
Characterising the RNA-binding protein atlas of the mammalian brain uncovers RBM5 misregulation in mouse models of Huntington’s disease

RNA-binding proteins (RBPs) are key players regulating RNA processing and are associated with disorders ranging from cancer to neurodegeneration. Here, we present a proteomics workflow for large-scale identification of RBPs and their RNA-binding regions in the mammalian brain identifying 526 RBPs. Analysing brain tissue from males of the Huntington’s disease (HD) R6/2 mouse model uncovered differential RNA-binding of the alternative splicing regulator RBM5. Combining several omics workflows, we show that RBM5 binds differentially to transcripts enriched in pathways of neurodegeneration in R6/2 brain tissue. We further find these transcripts to undergo changes in splicing and demonstrate that RBM5 directly regulates these changes in human neurons derived from embryonic stem cells. Finally, we reveal that RBM5 interacts differently with several known huntingtin interactors and components of huntingtin aggregates. Collectively, we demonstrate the applicability of our method for capturing RNA interactor dynamics in the contexts of tissue and disease.

RNA-binding proteins (RBPs) are key regulators of gene expression, controlling a plethora of RNA processing events such as capping, splicing, editing, transport, translation, degradation and storage. Altogether, RBPs and RNAs constitute a sophisticated network of dynamic ribonucleoprotein particles (RNPs), where each RBP is engaged in specific step(s) of the RNA-processing pathway. Alterations of the RNA-binding properties of RBPs affect RNP formation and RNA processing, and can result in disorders ranging from cancer to neurodegenerative diseases.

In the brain, RNA processing is necessary for neurogenesis, differentiation, synaptic plasticity and other neuronal-specific functions. Alternative splicing occurs at a significantly higher rate in the brain compared to other tissues and has determining roles in neuronal development, neuronal activity and for the functions of...
neuronal proteins. Likewise, neuronal activation dependent RNA localization and translation underlie synaptic plasticity, memory, axon guidance and regeneration. Altogether, the brain hosts one of the most abundant and diverse RNA landscapes, an observation that must be supported by the existence of complex post-transcriptional regulation mechanisms. Accordingly, many RBPs have higher expression levels in the brain compared to other tissues, specific expression patterns and exert brain specific functions; e.g., during transport to axons and dendrites, where RBPs protect mRNAs from degradation and premature translation.

Beyond this, mutations in specific RBP genes, such as FMR1 in fragile X syndrome and PABPN1 in oculopharyngeal muscular dystrophy, have been linked to several neurological and neurodegenerative diseases. Huntington's disease (HD) manifests in atrophy of the striatum, involuntary movements, psychiatric disturbances, and loss of cognition. It is caused by a CAG repeat expansion in the HTT gene leading to the expression of a mutant huntingtin (HTT) protein that is toxic to the cells and forms protein aggregates. For HD and other neurological diseases, aberrancies in splicing have previously been described, suggesting a role for RBPs in neurological pathology. Accordingly, a comprehensive atlas of the RNA interactors responsible for the regulation of post-transcriptional RNA processing events in the brain could lead to novel mechanic insights to neurological disease.

In the last decade, several mass spectrometry (MS)-based methods allowing for global and unbiased identification of RBPs have been developed, with some of these also capable of delineating the specific regions within RBPs directly binding the RNAs. However, experimental constraints have until now prevented the application of such methods to the study of RBPs directly in animals or organs. Here, we describe a streamlined workflow based on the augmentation of our peptide Cross-Linking and Affinity Purification (pCLAP) methodology, which we use to decipher the protein RNA interactome in the mammalian brain. Collectively, we identified 526 RBPs and among these, discovered 86 proteins not previously annotated as RNA-binding nor identified in any global cell culture-based RNA-interactome capture experiment, including several synaptic vesicle proteins and metabolic enzymes. Using cross-linking immunoprecipitation (CLIP) analysis, we confirmed the RNA-binding properties of several of these brain-specific RBPs, further demonstrating the utility of brain-pCLAP for studying RBPs in a tissue-specific context. We have further characterized the RBP landscape in brain tissue from the R6/2 HD mouse model and revealed misregulation of the RNA-binding ability of the alternative splicing factor RBM5, despite no change of its expression. Using CLIP analysis, we found that RBM5 binds differentially to several transcripts encoding proteins involved in neurodegeneration or with roles in HD. RNA-seq analysis revealed that these changes correlated with alteration in transcript expression and splicing. Similar changes were also observed in the R6/1 mouse, another model for HD prior to neuronal loss and gliosis. Furthermore, performing loss- and gain-of-function experiments in human neurons, we validated the regulatory role of RBM5 for the splicing changes observed in the HD mice, demonstrating the relevance of our findings in a human context. Finally, co-immunoprecipitation (Co-IP) and proteomic characterization of the protein interactors of RBM5 uncovered a significant overlap between the protein interactors of RBM5 and HTT. Some of these interactions with RBM5 were changed in the HD mouse brain, suggesting a previously characterized link between HTT and the misregulation of RBM5 function in HD. Taken together, this work represents a powerful resource for the identification of tissue specific RBPs and provides the foundation for a better understanding of how post-transcriptional regulation is controlled in tissue and changed during disease.

Results

Establishment of the brain-pCLAP methodology

To globally identify RBPs and study their dynamics in the brain, we adapted and improved our previously published pCLAP methodology to develop brain-pCLAP. As most other RNA-interactome identification methods, it relies on UV-based cross-linking to capture RNA-protein interactions in vivo. As UV-light does not efficiently reach the inner layers of tissue, gentle dissociation of brain cells prior to UV irradiation was first performed to ensure efficient cross-linking of the RNA-protein interactions (Supplementary fig. 1a–d). To specifically capture RNA-binding regions, cells were lysed and proteins digested with LysC protease, leaving only the RNA-binding regions cross-linked to RNA. Subsequent pull-down of poly-adenylated RNA using oligo-(dT) beads allowed efficient isolation of these RNA-bound peptides, which were then further digested by trypsin and identified via MS analysis (Fig. 1a). Additionally, a pre-cleanup step using unconjugated beads was added to our original workflow, which results in lower variance and tighter clustering of replicates (Fig. 1b and Supplementary Fig. 2a–c) and an overall three-fold increase in high-confidence identification of RNA-binding peptides (Supplementary Fig. 2d, e). Altogether, these improvements allowed us to perform pCLAP from the brain (brain-pCLAP) using as little as a single mouse brain for each independent replicate (in total) with one hemisphere exposed to UV-cross-linking while the other non-cross-linked hemisphere served as a control.

Peptides significantly enriched in the cross-linked brain samples compared to the non-cross-linked counterparts were first identified as previously described (referred to as Filter 1; Fig. 1c). Among these, a strong enrichment of peptides belonging to proteins with canonical RNA-binding domains (RBDs) was observed, confirming that our pull-down worked efficiently on brain tissue (Fig. 1c, in black). For additional stringency, a second filtering step (Filter 2) was introduced, for which the ratio of peptides enriched in the cross-linked compared to non-cross-linked samples for each protein passing filter 1 was quantified (see Supplementary Fig. 3 for details) and only proteins with a fraction above 60% were retained. The validity of this approach was supported by the observation that proteins containing canonical RBDs generally had a higher fraction of peptides enriched in the cross-linked samples (Supplementary Fig. 2f, in red), whereas this was not the case for many proteins that are highly abundant in the brain proteome (Supplementary Fig. 2g, in grey).

Among the resulting pool of candidate RBPs, seventy percent have previously been annotated as RNA-binding (Fig. 1d) and constituted a high fraction of all proteins with known canonical RBDs identified in the brain proteome (Fig. 1e). Together, these results demonstrated the high specificity of brain-pCLAP. Moreover, the stringency of our filtering criteria did not come at the cost of sensitivity, as it excluded a large pool of proteins enriched for very general processes, whilst only removing 3% of proteins containing canonical RBDs (Fig. 1e and Supplementary fig. 2h). To further assess the sensitivity of our methodology, we next compared the sequencing depth of brain-pCLAP to cell culture based RNA interactome studies. This demonstrated that despite the stringency of our workflow, similar depth of sequencing was achieved (Fig. 1f and Supplementary Fig. 2i). Altogether, our results demonstrated that brain-pCLAP enables the identification of the brain RNA-interactome with high specificity and sensitivity.

The brain RNA-interactome contains candidate RBPs associated with neuronal functions

In total, we confidently identified 526 proteins binding RNAs in the mouse brain. Among these, 431 have previously been identified across 14 different mass spectrometry based RNA-interactome studies from mouse and human cell lines (Fig. 1g and Supplementary Data 1). As expected, gene ontology (GO) term analysis of these proteins showed strong enrichment for ribonucleoprotein complexes (Fig. 1h). The 95
other proteins were enriched for synaptic proteins (Fig. 1h) and also included nine known brain specific RBPs, including RBFOX1, RBFOX3 and SRRM4, with known functions in neuronal development. The 86 brain-specific candidates not previously described as RBPs (Fig. 1g) included eight metabolic enzymes and twelve synaptic vesicle proteins (SVPs) (Fig. 1i), nine of which are membrane bound. These observations support the mounting evidence that proteins such as metabolic enzymes can bind RNA, despite this not being their main described function (so called ‘moonlighting’ RBPs). Our data further suggest that membrane bound SVPs could similarly have ‘moonlighting’ functions as RBPs (Fig. 1i and Supplementary Data 1).

We then took advantage of the ability of pCLAP to pinpoint the regions of RBPs that interact with RNA. To demonstrate this ability for brain-pCLAP, all the identified peptides were mapped onto all protein domains reported in the pfam database. From this, we observed a strong enrichment for known RBDs (Supplementary Fig. 4a, b), with 55% of the peptides mapping to canonical RBDs, and 5% to non-canonical RBDs (Supplementary Fig. 4c, d and Supplementary Article).
and Supplementary Fig. 4f, g). We employed our pCLAP data to identify the content of the complex was confirmed by functional analyses. In contrast, both the splicing activity and/or RNA-binding ability54,55. In conclusion, while revealing the RNA-binding capability in the HD mice (Fig. 3a and Supplementary Data 2). This affected peptide corresponded to the alternative splicing factor RBM546. For both proteins, an RNase sensitive RNP complex could be detected, collapsing at the expected protein size at the highest RNase concentration used. No RNP complex was observed without cross-linking or for the same experiment done with GFP only (Fig. 2c and Supplementary Fig. 4h). Similar results were observed for other candidates, including the iron-storage protein FTH1, Zinc-finger protein ZCCHC10, synaptic vesicle protein SV2A, as well as membrane bound proteins RTN1 and PRAF2 (Supplementary Fig. 4h)46,48 and two additional membrane bound SVPs; SYP and VAMP1 (Supplementary Fig. 4i). Collectively, these data further confirmed the ability of brain-pCLAP methodology to identify RBPs.

**Exploration of the brain tissue of the HD mouse model R6/2 by brain-pCLAP reveals changes in the RNA-binding ability of RBM5** To demonstrate the utility of brain-pCLAP in a disease context, we next applied our workflow to the HD mouse model, R6/2, since perturbations in splicing have been reported in the brains of deceased HD patients and in this representative mouse model13,14. We investigated if these defects may derive from aberrant RBP activity by performing brain-pCLAP on four R6/2 HD brains and four wild-type (WT) brains from 12 weeks old sibling mice and comparing the data. As for the previous experiment, we first confirmed that RBPs from both WT and HD samples were identified with high reproducibility, specificity, and sensitivity across all replicates (Supplementary Fig. 5a–c and Supplementary Data 2).

From the quantitative comparison of the RNA-binding events between the R6/2 HD model and WT mouse brain samples, we identified a single peptide to be significantly affected in its RNA-binding capability in the HD mice (Fig. 3a and Supplementary Data 2). This affected peptide corresponded to the alternative splicing factor RBM546, a known RBP which contains two RRM domains and two ZF-domains14. In total, brain-pCLAP identified three RNA-binding peptides from RBM5 in the WT mouse brain tissue, which mapped to the two RRM domains (Fig. 3b). This is in accordance with previous findings that deletion of the two RRM domains is sufficient to abolish the RNA-binding ability of RBM52. However, only one peptide (spanning the amino acid sequence 104-115) was depleted in the brain-pCLAP samples from the R6/2 compared to the WT brain tissue, suggesting a difference in the RNA-binding ability of this particular RRM in the HD mouse model (Fig. 3a, b). In fact, the affected peptide was not detected in any of the analysed R6/2 samples, whereas it was consistently identified across all eight WT samples analysed throughout this study (Fig. 3c). However, neither the expression of this peptide nor the overall expression of RBMs in the proteome was changed in the HD mouse brain tissue (Fig. 3d, e, Supplementary Fig. 5d, and Source data)14. Therefore, the observed change in the RNA-binding ability of RBM5 could not be explained by differential expression of a unique RBM5 isoform or general changes in RBM5 expression in the HD mouse brain tissue. These data imply that the RNA-binding ability of the initial RRM domain of RBM5 undergoes specific alterations in the HD mouse.
brain, though we cannot discount the possibility that other mechanisms may play a role in this process.

Enrichment of neurodegeneration and HD pathways among RNAs differentially bound by RBM5 in R6/2 mouse brain tissue

Next, we wanted to further investigate the RNA-binding capabilities of RBM5 in the HD model. To this end, we established high-throughput sequencing (HITS)-CLIP\textsuperscript{39} on endogenous RBM5 using two different antibodies (AbM and AbR), and applied it to WT and HD mouse brain tissues (Fig. 4a and Supplementary Fig. 6a, b). Principal component analysis (PCA) showed that the samples grouped closer by genotype rather than by antibody-type supporting the implementation of a successful CLIP experiment (Fig. 4b). For stringency, only read clusters identified in both antibody experiments (AbM and AbR) and showing
at least two-fold enrichment over the IgG controls were considered genuine RBM5 binding sites (Supplementary Fig. 6c). From this, we identified 4375 and 3559 transcripts as RBM5 targets from WT and HD mouse brain samples respectively (Fig. 4c, Supplementary Fig. 6c, and Supplementary Data 3). For both genotypes, we found that ~60% of the RBM5-binding sites located to introns, with a strong enrichment less than 100 nt upstream of the 3' splicing site (ss) in relation to intron–exon junctions (Fig. 4d). This is in agreement with reports showing that RBM5 regulates the utilization of weak 3' ss41,67,69. Gene ontology (GO) analysis of RBM5 targets showed enrichment of pathways for neurodegeneration, including HD, while a significant number of RBM5 targets have been shown to localize to the synapses for localized translation (Fig. 4e, f)70,71. In agreement with RBM5 being a pro-apoptotic tumour suppressor gene67,72,73, caspase and cyclin transcripts were also bound by RBM5 (Supplementary Fig. 6d). Comparing the targets for the two genotypes, we identified 538 transcripts differentially bound by RBM5 in the R6/2 mouse brain tissue (Fig. 4g). These differentially bound transcripts were further enriched for pathways of neurodegeneration and HD (Fig. 4h). Network visualization of the ten most significantly enriched GO terms showed that many of these transcripts have roles in several interconnected neurodegenerative diseases (Fig. 4i).
Expression and splicing of RBM5 targets are altered in the R6/2 mouse brain

We next investigated if the differential binding of RBM5 was associated with a change of expression of its targets by performing RNA-seq transcriptome analysis on brain tissue from the same WT and HD mice used for the CLIP analysis. As expected, PCA analysis showed grouping of the samples by genotype (Supplementary Fig. 6e), with more than 3000 transcripts differentially expressed in R6/2 mouse brain tissue (Supplementary Fig. 6f and Supplementary Data 4). GO-term analysis of these transcripts showed enrichment of genes involved in metabolic pathways, synaptic signalling pathways and viral and immune responses (Fig. 5a), which is in agreement with previous reports [53,74,75]. Interestingly though, and contrary to RBM5-CLIP, we did not observe specific enrichment for neurodegeneration pathways genes,
suggesting a further specific association of RBM5 with neurodegenerative relevant transcripts. Comparison between our RNA-seq data, our RBM5-CLIP changes and published brain proteome data from the same R6/2 HD strain showed a statistically significant overlap. For 55% (290 of the 532) of the transcripts differentially bound by RBM5 in the R6/2 mouse brain, we also observed changes in expression levels for the corresponding transcripts or proteins (Fig. Sb and Supplementary Fig. 6g).

Our transcriptome data furthermore revealed that 3300 RNAs were differentially spliced, with significant changes in the inclusion of specific exons or introns (Supplementary Fig. 6h and Supplementary Data 4). Comparison between the differentially spliced transcripts and the transcripts bound differentially by RBM5 in R6/2 mouse brains revealed a significant overlap between the two datasets (Fig. 5c), including many neurodegeneration-related genes (Fig. 4i), suggesting a role for RBM5 in regulating the splicing of these genes.

To confirm that our observations indeed represent changes in alternative splicing, we chose three transcripts (Atrx, Ptpn11 and Adams10) differentially bound by RBM5 and differentially spliced in the diseased brain for further investigation (Fig. 5d–f, left side). In accordance with the RNA-seq data, we also observed splicing changes of specific introns for all three candidates via RT-PCR analysis (Fig. 5d–f, right side), confirming that the differential splicing correlated with RBM5 binding changes in the R6/2 mouse brain. Altogether, our results demonstrate that RBM5 binds specific RNA targets in the brain, including neurodegenerative-related transcripts, and that the binding to these targets and their splicing are affected in a mouse model of HD.

Finally, in agreement with proteomics and western blot data, we did not see any changes in the expression or splicing of RBM5 itself (Supplementary Data 5), confirming further that the change in RBM5 function in the R6/2 mouse brains is uniquely regulated at the level of its RNA-binding ability.

Splicing changes observed in R6/2 mouse model were demonstrated to be regulated by RBM5 in human neurons, and detected in another HD mouse model as well as in HD patient samples. The experiments in R6/2 mice demonstrated that RBM5 binding changes significantly overlapped with splicing changes of its target RNA. To ascertain the causal link between these events, we tested if the splicing of RBM5 targets was affected upon knock-down (KD) or overexpression (OE) of RBM5.

To further extend the analysis to human cells, we differentiated human embryonic stem cells (hESCs) towards lateral ganglionic eminence (LGE) fate, as the LGE contains the most affected neuronal subtypes in HD. RBM5 was then KD or OE using lentiviral transduction (Fig. 5g). Five independent differentiations and transductions were performed. RBM5 KD and OE were validated by RT-qPCR (Fig. 5h and Supplementary Fig. 7a). Moreover, proper differentiation and maturation of the neurons in all conditions were validated by confirming the expression of the expected neuronal markers samples over exons and flanking intronic regions for all sample groups. Overlap of RBM5 RNA targets identified by CLIP and RNAs localizing to the synapse (p value calculated by one-tailed Fischer exact test). GO term enrichment analysis for KEGG pathways on RBM5 RNA targets identified by CLIP. Number of genes encoding transcripts that are bound differentially by RBM5 in HD. GO term enrichment analysis for KEGG pathways for the transcripts bound differentially by RBM5 in HD (p values in f, h were calculated using one-sided Fischer's exact test). Interaction between RBM5, RNA processing factors and Huntington interactors are perturbed in the R6/2 mouse brain Since RBM5 expression was not changed in the HD mouse brain, we wanted to explore what may be causing the specific misregulation of its RNA-binding ability. RNPs are composed of a defined combination of proteins fine-tuning the activity of each other and the polyglutamine expansion in HTT introduces perturbations in the proteome. We therefore reasoned that the misregulation of RBM5 in controlling splicing in the R6/2 brain may be caused by an altered interaction with its protein partners. To test this hypothesis, we identified the RBM5 protein-interactome via affinity-purification mass spectrometry (AP-MS) from WT and HD mouse brain samples using the same two anti-RBM5 antibodies (AbM and AbR) used for CLIP (Fig. 6a).

Overall, we obtained excellent reproducibility between replicates and samples clustered based on genotype on a PCA plot (Supplementary Fig. 8a, b). After filtering out unspecified binders and considering only interactors significantly enriched with both antibodies (Fig. 6b and Supplementary Fig. 8c, d), we identified a total of 617 RBM5 protein interactors in the WT brain and 600 in the HD brain, with high overlap between the two antibodies, providing a total of 619
protein interactors (Fig. 6b and Supplementary Data 6). In agreement with the literature, RBM5 interactors were highly enriched in RNA processing and splicing factors (Fig. 6c), including U2AF2 (U2AF65), a protein known to interact with RBM5 to co-regulate several splice events43,69,78. Interestingly, a significant number (40%) of the identified RBM5 interactors also constitute known HTT interactors (Fig. 6d)79,80, with the shared interactors between RBM5 and HTT highly enriched for proteins involved in mRNA metabolic processes, neuron specific processes and Huntington’s disease (Supplementary Fig. 8e). This was specific to RBM5, as a much lower overlap was observed between proteins interacting with HTT and the interactomes of three RBPs unrelated to this study (Supplementary Fig. 8f)81–83.

Finally, we uncovered 14 proteins that exhibit altered interaction with RBM5 in the HD mouse brain, including several RNA processing and splicing factors as well as synaptic signalling factors (Fig. 6e, f and Supplementary Data 6). One of these, DDX23 is a splicing factor
RBM5 expression was unchanged, as shown by us and others, with classical proteomics or sequencing approaches. In line with this, while reveal subtle regulatory changes, not associated with change in context, we observe decreased interaction with six proteins that binding ability of RBM5 observed in R6/2 mouse brains. Intriguingly, among the 14 proteins interacting differentially with RBM5 in the disease context, we observe decreased interaction with six proteins that have previously been identified to interact with HTT, five of which are in HTT aggregates. The molecular mechanisms of how the reduced availability of several RBM5 protein interactors sequenced into HTT aggregates affects RBM5 function should be interesting to investigate in future studies. Conversely, we observe increased interaction between RBM5 and DDX23. The latter is required for the transition of the spliceosome from its inactive confirmation to its active confirmation, whereas by contrast, RBM5 has been reported to block this transition. Among the other regulated RBM5 interactors, six of the proteins that interact less with RBM5 in the HD brain constitute known interactors of HTT, with five of these also reported to localize to HTT aggregates. Taken together, our data therefore demonstrate that the protein-protein interaction landscape of RBM5 is disturbed in the HD mouse brain, which could be a cause for RBM5 misregulation. It further suggests that this perturbation could be caused by a change of availability with interactors known to be sequestrated into HD-related aggregates.

**Discussion**

RBPs can have brain specific functions and their malfunctioning is a known contributor to neurological disorders. To understand the range of RBP functions and their contribution to disease in its whole complexity, it is critical to study RBPs directly in tissues and organs. In this study, we report the development of brain-pCLAP that allows studying the RNA-binding ability of proteins globally in tissue. Brain-pCLAP provides two dimensions of information. Firstly, it allows global identification of RBPs and their RNA-binding regions in the brain. This offers a basis for further studies and broader understanding of proteins regulating post-transcriptional processes in this organ. Here, we demonstrated the RNA-binding ability of several brain-specific proteins not previously characterized as RNA-binding, including several metabolic enzymes and synaptic vesicle proteins, providing further evidence in support of proteins `moonlighting` as RBPs. Secondly, brain-pCLAP provides information on disease related changes across RBPs and individual RNA-binding regions. This can be used to unbiasedly identify RBPs that have compromised functions in disorders affecting the brain. We demonstrated this by applying brain-pCLAP to the R6/2 HD mouse model and found that the RNA-binding ability of the alternative splicing factor RBM5 is altered. Furthermore, the ability of brain-pCLAP to identify specific RNA-binding regions of RBPs can reveal subtle regulatory changes, not associated with change in expression or deleterious mutations, which would therefore evade classical proteomics or sequencing approaches. In line with this, while RBM5 expression was unchanged, as shown by us and others, we observed that the RNA-binding properties of the first RRM of RBM5 were specifically altered in HD mice.

RBMS is a ubiquitously expressed RBP known to regulate mRNA and protein levels, as well as alternative splicing of genes involved in regulation of apoptosis, cell cycle, cytoskeleton, and drug metabolism. RBMS can both stimulate and suppress splicing at specific splice sites via different mechanisms. Notably, these opposite mechanisms involve different protein-protein and RNA-protein interactions, suggesting a complex mechanism of regulation for the activity of RBMS. One characteristic of RBMS that could allow for highly specific modes of action is that its RBDS seem to have distinct regulatory roles, with mutations in either RRM domain shown to differently affect RBMS function and specificity. Furthermore, the second RRM domain of RBMS has been shown to adapt different conformations leading to different target specificities, suggesting a mechanism through which the individual RRMs could regulate the function of RBMS. In support of the separate functional roles of the RRM domains of RBMS, we find that the RNA-binding properties of the first RRM are altered in HD mice and consequently report the identification of ~500 target transcripts bound differentially by RBMS in R6/2 mouse brain tissue. These targets are significantly enriched for transcripts involved in neurodegenerative diseases, including HD, and overlap with changes in transcript and protein expression levels and splicing changes. This suggests a mechanism where the misregulation of the function of the first RRM of RBMS in the HD mouse brain may lead to aberrant expression and splicing of several of its HD relevant targets (Supplementary Fig. 9), which could contribute to the aetiology of this disease. Although the consequences of RBMS misregulation have been demonstrated to affect very different biological contexts, including tumour proliferation, fertility or traumatic brain injury, the proposed underlying mechanism for all of them is the same: mis-regulation of apoptotic genes leading to apoptosis. Here, our data suggest that RBMS may have a role in directly regulating the expression and splicing of transcripts relevant to neurodegenerative diseases, supporting a role for RBMS in neurodegeneration via other pathways than apoptosis.

Furthermore, we have demonstrated that the RBMS protein-protein interaction landscape is perturbed in the HD mouse model. Considering firstly that no RBMS expression, splicing or isoform changes were observed in the HD mouse brain in this or previous studies in R6/2 mice and secondly that RBMS function in concert with one another, we propose that the changes in the interaction of RBMS with other proteins could lead to the misregulation of the RNA-binding ability of RBMS observed in R6/2 mouse brains. Intriguingly, among the 14 proteins interacting differentially with RBMS in the disease context, we observe decreased interaction with six proteins that have previously been identified to interact with HTT, five of which are in HTT aggregates. The molecular mechanisms of how the reduced availability of several RBMS protein interactors sequenced into HTT aggregates affects RBMS function should be interesting to investigate in future studies. Conversely, we observe increased interaction between RBMS and DD2X3. The latter is required for the transition of the spliceosome from its inactive confirmation to its active confirmation, whereas RBMS has been shown to prevent this transition. This suggests regulatory interplay between the two proteins, which could be perturbed in HD and could contribute to the splicing changes observed. Altogether, our multi-omics study allows us to suggest a working model where the changes of interaction between RBMS and its protein partners would lead to the misregulation of its RNA-binding ability, leading to aberrant splicing of its targets (Fig. 7).
This includes many neurodegenerative- and HD-related RNAs, whose dysregulation could potentially affect the overall expression and function of several genes contributing directly to HD pathology (Supplementary Fig. 9).

Finally, we demonstrated that many transcripts bound differentially by RBM5 in the brain of R6/2 mice undergo alternative splicing changes also in R6/1 mice, mimicking HD before the signs of neurodegeneration43,44, and in HD patients44. This suggests that RBM5 misregulation and the resulting alternative splicing changes are an attribute of early HD development and not a secondary consequence of the disease. Furthermore, we showed that the alternative splicing events that are altered in the HD mouse brains are regulated by RBM5 in human neurons differentiated from stem cells, demonstrating the potential implication of our findings to the human brain context.
While our data all point to a change in the RNA-binding ability of RBM5 in HD, we cannot exclude other explanations overlooked by the limitation of our methods and analyses. Additional investigations using human samples will also be needed to further characterize the contribution of RBM5 misregulation to HD in patients. Lastly, as standard practice in the field when this work was initiated, only male mice were studied to reduce variation and to avoid gender specific effects that could not be pinpointed in our current setup. Therefore, and while some of our findings were supported by experiments done in female cell lines or using data from human HD patient from both sexes, we cannot fully exclude that some of our observations are limited to male individuals.

In conclusion, we developed the brain-pCLAP methodology, which allowed establishment of a comprehensive atlas of RBPs in the mammalian brain. This represents a powerful resource for understanding the mechanisms of post-transcriptional regulation and gene expression control in the brain. Our methodology allows the identification of the RBP interactome of metazoan cells under native conditions without the need for expansion in culture, which is an important technological milestone in the field of RNA biology. Finally, we identified and validated RBM5 as an aberrant RNA binder in models of HD, explaining changes observed in alternative splicing for this disease and demonstrating the utility of our approach to study RBP function in neurodegenerative disorders.

**Methods**

**Mouse strains**

R6/2, transgenic for exon 1 of the human HTT gene, originated from The Jackson Laboratory (Bar Harbor, ME, USA) and were maintained by backcrossing males to CBA/J3B6 females (Taconic, Denmark). The mice were kept under specific pathogen-free conditions at a 12 h light/
12 h darkness cycle, at 21 °C (20–24 °C temperature range) and at a humidity of 55 ± 10% in standard polystyrene cages with ad libitum access to standard chow and water. DNA was extracted from ear punches and used for genotyping. The repeat length was between 190 and 200 CAG throughout the experiment. Twelve-week-old male mice were used for all experiments. WT littermates without the HTT transgene were used as controls. Experiments were performed in accordance with the Danish Animal Experiments Inspectorate’s guidelines (permit 2007/561–1345), the Danish Working Environment Authority (permit 20070033239/4), and European Commission Directive 86/609/EEC for animal experiments.

Isolation of mouse brains, tissue processing and homogenization for brain-pCLAP

The mice were euthanized by cervical dislocation and the brains were collected on ice. The two brain hemispheres were separated and each cut into four pieces. The pieces from each hemisphere were moved to a TenBroeck homogenizer on ice, containing 5 mL of ice-cold HBSS without Ca2+ and Mg2+ (14175129; Thermo Fischer Scientific) and the brain cells were dissociated from the tissue by three gentle strokes with the homogenizer. The suspension was subsequently passed through a 50 μm nylon filter (04-004-2327; Sysmex America) using a syringe plunger, resulting in a single cell suspension. The homogenizer and filter were then both washed with HBSS (Mag, -Ca) to collect all cells. The cells from the right hemisphere were UV-cross-linked twice with UV-light at 254 nm 0.175 J/cm2 (Dr. Gröbel GmbH), whereas cells from the left hemisphere were UV-cross-linked twice. The cell suspension was then spun down at 4 °C at 500 × g for 10 min and followed by immediate freezing of the cell pellet on dry ice. In all other respects, the two halves were treated in the same way. The cell suspension was then spun down at 4 °C at 500 × g for 10 min and followed by immediate freezing of the cell pellet on dry ice. The cells were lysed with lysis buffer containing 6 M GndHCl, 100 mM Tris (pH 8.0), 1 mM EDTA, 5 mM tris(2-carboxyethyl)phosphine (TCEP; C4706, Sigma Aldrich), 10 mM chloroacetamide (CAA; 22790, Sigma Aldrich). Lysis was followed by immediate sonication at 70% amplitude (Sonics) three times for 20 s. Samples were kept on ice between the sonication cycles. Samples were cleared by centrifugation at 14,000 × g for 15 min at 4 °C and the supernatant was collected. Protein concentration was measured using the Bradford protein assay and 8–10 mg total protein was used per pull-down. LysC (Wako; protein:LysC ratio = 100:1) was added to each sample and LysC digestion was performed for 4 h at room temperature. Samples were cooled down on ice and diluted to a GndHCl concentration of 2 M with a dilution buffer (100 mM Tris (pH 8.0), 1 mM EDTA, 5 mM TCEP, 10 mM CAA).

Immunoprecipitation with oligo(dT) for brain-pCLAP

For pre-clearance, half of the lysed brain samples (4 cross-linked and 4 non-cross-linked) were incubated with empty magnetic beads (Custom made, NEB) for 1 h at 4 °C on a rotator. The beads were pelleted on a magnetic rack (DynalMag-2 Magnet, 12321D, Thermo Fisher Scientific). The cleared supernatants were used for oligo(dT) pull-downs. For enrichment of RNA and the cross-linked LysC peptides representing the RNA-binding regions of the proteins in the brain, the samples were incubated with magnetic oligo(dT) beads (S1419S, NEB) at 4 °C on a rotator for 1 h. The beads were pelleted using the magnetic rack. Beads were washed three times with washing buffer (2 M GndHCl, 100 mM Tris (pH8.0), 1 mM EDTA, 5 mM TCEP, 10 mM CAA). After the last wash, the supernatant was removed and the beads were pelleted with a quick spin. Samples were heat eluted at 80 °C in elution buffer (20 mM Tris (pH 8.0), 1 mM EDTA) on a shaker at 400 rpm. NaCl was added to each sample to a concentration of 0.1 M followed by RNase treatment using a mixture of RNase A and T1 (EN055L; Thermo Scientific), the samples were incubated for 1 h at 37 °C on a shaker at 350 rpm. This was followed by addition of trypsin (Sigma; peptide:trypsin ratio = 100:1) to each sample and incubation overnight at 37 °C on a shaker at 350 rpm. Samples were acidified by addition of 10% Trifluoroacetic acid (TFA) to lower the pH of the sample to 2–3, followed by pelleting all undigested proteins by centrifugation at 14,000 × g for 15 min at 4 °C. The pellet was discarded and the supernatant was used for stage 1 CID.

During this study, we tested brain-pCLAP without the pre-clearance step with empty beads, which is shown for comparison in Fig. 1b and Supplementary Fig. 2a–e (noted as XL PD). We also saved and eluded the peptides captured with the empty beads during the pre-clearance and analysed them by MS, these are shown for comparison in Fig. 1b and Supplementary Fig. 2a–c (noted as EB-PD).

Clean-up and concentration on SCX and C18 StageTips for brain-pCLAP

Digested RNA was removed using SCX StageTips. Four disks of SCX material (Empore SPE disks, 66888-U, Sigma Aldrich) were pushed into a p200 pipette tip. The SCX material was activated by individually passing 200 μL of the following buffers in the specified order through the material, using centrifugation (800 × g): MeOH, 20% Acetonitrile (ACN), 34967.25L. Sigma Aldrich) with 0.1% TFA, SCX buffer pH12 (20% ACN, 20 mM boric acid, 20 mM phosphoric acid, pH adjusted to 12 with NaOH) and 20% Acetonitrile/ 0.1% TFA Stage-Tips were not centrifuged to complete dryness at any point. The samples were loaded onto the activated SCX StageTips and the flow-through was discarded. The peptides were eluted with 200 μL SCX-buffer pH12 and concentrated to 100 μL until the ACN was evaporated using Vacufuge (Eppendorf). C18 StageTips were used to desalt and concentrate the samples as described before. Two disks of C18 material (Empore SPE Discs, 66883-U, Sigma Aldrich) were pushed into a p200 pipette tip. The C18 material was activated by individually passing 100 μL of the following buffers in the specified order through the material, using centrifugation (800 × g): MeOH, 80%, ACN with 0.5% Acetic acid, 0.5% of Acetic acid. The concentrated samples were loaded onto the activated C18 StageTips and washed once with 0.5% of Acetic acid. The loaded StageTips were run dry and stored in the fridge. Samples were eluted right before MS using 40 μL of 40% ACN and 0.5% Acetic acid. The samples were concentrated to below 8 μL and the acetonitrile evaporated in a Vacufuge at 45 °C. 1 μL or more of 5% Acetonitrile and 0.1% TFA (T6508-500ML, Sigma Aldrich) was added to the samples to acidify the sample and bring the final volume to 9 μL.

MS analysis of brain-pCLAP samples

Each technical replicate was analysed as a single shot on the Q Exactive HF (Thermo Fischer) mass spectrometer coupled to an EASY-nLC 1200 System (Thermo Fischer) with 15 cm long in-house prepared column, filled with ReproSil-Pur 120 C18-AQ, 1.9 μm (r119.aaq; Dr. Maisch). Peptides were separated out on a 77-min low pH gradient with a mobile phase of 0.1% Formic acid (1.00264.1000, VWR) and an Acetonitrile concentration gradient ranging from 0% to 80%. The mass spectrometer was operated using the ‘sensitive method’ described previously. More precisely, ions were accumulated to a target value of 1e6 and MSI spectra (m/z 300–1750) were acquired using the Orbitrap at a resolution of 70 000 resolution (for m/z 200). The 12 most intense ions that were
multiply charged were isolated with a fixed injection time of 120 ms, fragmented by higher-energy collisional dissociation (HCD) with HCD collision energy 25% and analysed in the orbitrap with a resolution of 35,000 resolution.

**Brain-pCLAP data analysis**

Raw mass spectrometry data files were analysed by the MaxQuant (v1.4.1.1 and v1.5.0.38) software suite using standard settings, supported by the Andromeda search engine. Briefly, data were searched against a concatenated target/decoy (forward and reverse) version of the UniProtKB (11.07.2016) database encompassing 71,434 protein entries. We used the step-by-step protocol of the MaxQuant (version 1.5.0.38) software suite to generate MS/MS peak lists that were filtered to contain at most six peaks per 100 Da interval prior to the Andromeda database search. The mass tolerance for searches was set to a maximum of 7 ppm for peptide masses and 20 ppm for HCD fragment ion masses. Data were searched with carbamidomethylation as a fixed modification and protein N-terminal acetylation and methionine oxidation as variable modifications. A maximum of two miscleavages were allowed while requiring strict trypsin specificity. All the replicates were analysed together, and match between runs was turned on. Reverse hits and contaminants were removed from the protein and peptide data. The peptide.txt output file was then analysed in Perseus (version 1.5.1.2 and 1.6.1.2.; Max-Planck Institute of Biochemistry, Department of Proteomics and Signal Transduction, Munich, Germany). Pearson correlations between replicates and samples from different sample groups were calculated using column correlations in Perseus. Peptides that had intensities from less than three replicates in one of the sample groups were removed before statistical analysis. Missing values, including intensities for peptides identified in only the cross-linked or non-cross-linked sample, were imputed on the basis of the normal distribution of the intensities in each sample using standard parameters in Perseus. All further analysis was done with the four cross-linked and non-cross-linked replicates from the pre-cleared samples.

The cross-linked samples were compared with the non-cross-linked sample using the two-tailed Student's t test in Perseus, with an FDR of 0.05 and s0 of 0.1, to determine which peptides were significantly enriched in the cross-linked samples. Gene ontology (GO) and InterPro motif enrichment analyses were conducted using GeneCodis and PANTHER version 11. Peptide localization in proteins was assessed using MaxQuant Viewer and Perseus by mapping sequences onto known Pfam domains as reported in the Pfam database.

Abundance distribution analysis was done by extracting iBAQ values for each protein identified by brain-pCLAP from a deep brain proteome data, which signifies the abundance of the proteins in the brain proteome. The same was done for cell-based RNA-interactome capture studies, where iBAQ values were extracted from a deep HeLa proteome. Differences in protein abundance distributions between brain-pCLAP and the brain proteome and pCLAP and other cell-based RNA-interactome studies compared to the HeLa proteome were calculated using a two-tailed, unpaired t test using the program Prism. The mean for the brain proteome was 29.31 and 24.7 for the HeLa proteome. The means of the other samples correspond to either brain proteome or HeLa proteome shown plus the mean difference shown under each box in the figure. p Values for comparisons of abundance distribution differences between Brain proteome vs. brain pCLAP and HeLa proteome vs. cell-based RNA-interactome capture experiments were given as <0.0001 by Prism.

For the R6/2 (HD) to WT littermates, all peptides identified as enriched in the cross-linked sample for either WT or HD or both were retained in the dataset and before comparison and subtracted mean normalization was done in Perseus, assuming that the overall intensity of the samples should be similar. The differences were assessed using two-tailed Student’s t test in Perseus (version 1.5.1.2).

**Culturing and transfection of HEK293T cells**

Human embryonic kidney cells (HEK293T cells (CRL-3216, female), acquired via the American Type Culture Collection.) cells were grown in DMEM glutation (31966-047, Gibco, Thermo Fischer Scientific), supplemented with 10% Fetal Bovine Serum (10270-106, Gibco, Thermo Fischer Scientific) 100 U/mL penicillin-streptomycin (15140-122, Gibco, Thermo Fischer Scientific), at 37 °C in a humidified incubator with 5% CO2. Cells in a 15 cm dish were grown to 30–40% confluency and transfected with a mixture of 1:1000 dilution of Lipofectamine2000 (11668019, Invitrogen, Thermo Fischer Scientific), 1:10 dilution of OptiMEM (31985026, Invitrogen, Thermo Fischer Scientific) and 4 µg of plasmid expressing GFP-tagged candidate RBPs, media was exchanged 3–4 h after transfection and cells were harvested after 2 days. Transfection efficiency was assessed with fluorescence microscopy on live cells and was generally around 70–90%, as well as by western blotting and blotting with an anti-GFP mouse antibody (IS1141460001; Roche). Proteins on the membrane were also visualized by Pierce S 0.1% (P7170-1L, Sigma-Aldrich) staining. All vectors expressing GFP-tagged candidate RBPs were ordered from GeneScript. Each of the following open reading frames was cloned into a pcDNA3.1(+)-C-eGFP vector backbone: NM_010239.2 (RBM5), NM_027558.1 (PGRMC1), NM_001275.1 (PGRMC2), NM_133602.4 (P4F2), NM_153457.7 (RTN1), NM_022030.3 (SV2A), NM_010239.2 (FTH1), NM_026479.4 (ZCCHC10).

**GFP-based immunoprecipitation**

Immunoprecipitation was done using GFP-Trap MA magnetic beads (gtmA-20, Chromotek) according to the manufacturer’s instruction. Briefly, transfected HEK293T cell pellets were lysed (50 mM Tris-HCl, pH 7.5, 400 mM NaCl, 1 mM EDTA, 1% NP-40, 0.10% Na-deoxycholate, 25 U/mL benzozate (E1014, Sigma Aldrich) and 1 tablet per 10 mL) complete mini EDTA-free protease inhibitor cocktail (4939136001; Roche), sonicated at amplitude 70% (Sonics) for 20 s and spun down at 13,000 × g for 10 min at 4 °C. Lysate containing 2 mg of protein (measured by Bradford assay) per sample was added to the beads and incubated for 2 h at rotator at 4 °C. Beads were washed once with lysis buffer and twice with washing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) Samples were eluded in NuPAGE LDS Sample Buffer (4X) (NP0007, Novex, Thermo Fischer Scientific) and analysed on a Western Blot, blotting with an anti-GFP mouse antibody (IS1141460001; Roche). Proteins on the membrane were also visualized by Pierce S 0.1% (P7170-1L, Sigma-Aldrich) staining.

**Western blot analysis**

Western blotting was done using standard protocols, with the following antibodies. RBMS was visualized with mouse monoclonal anti-LUCAS1 antibody (200 µg/mL; sc-515419, Santa Cruz), with a dilution of 1:1000 in 5% bovine serum albumin (BSA). GFP was visualized with the anti-GFP mouse antibody (IS1141460001; Roche), with a dilution of 1:1000 in 5% BSA. GAPDH was visualized with the Rabbit polyclonal to GAPDH (ab9485; Abcam) antibody, with a dilution of 1:1000 in 5% BSA.

**Cross-linking and immunoprecipitation (CLIP)**

CLIP experiments were done following a protocol previously published and with the parameters described below. For CLIP on selected candidates, HEK293T cells were transfected with vectors expressing GFP-tagged proteins and cultured as described above. The cell pellet of one confluent 15 cm dish was used for each sample/condition and lysed in 1 mL PXL lysis buffer. Precipitation of cross-linked GFP-tagged RBP candidate–RNA complexes was done using GFP-Trap_MA magnetic beads (gtmA-20, Chromotek); 15 µL per sample. RNase A treatment was performed with addition of 10 µL of 1:100 or 1:1000 dilution of stock solution (Affymetrix, P/N:70194Y). Protocol
was carried out until the exposure of the radioactive SDS-PAGE. Phosphoimaging was done on a Typhoon FLA 7000 biomolecular imager. For RBM5-CLIP, R6/2 transgenic and WT mouse brain samples were harvested, homogenized and cross-linked as described for pCLAP. For each replicate, half a brain was lysed in 6 mL PXL lysis buffer and 1 mL of the lysate per sample was incubated with beads coupled to 20 μg RBM5 antibodies AbR and AbM or non-specific (IgG) antibodies. Antibody-coupled beads were prepared as follows: 50 μL of Protein A Dynabeads (ThermoFisher Scientific, 10002D) per sample were washed three times with cold PBS 0.02% Tween. For AbR, beads were then re-suspended in cold PBS 0.02% Tween and 7.5 μL of rabbit polyclonal anti-RBM5 antibody (HPA018011; Merck/ Sigma) and incubated on a rotator overnight at 4 °C. For AbM, beads were first incubated with 31.25 μL of a bridging antibody AffiniPure Rabbit Anti-Mouse IgG, Fc fragment specific (Jackson Immunoresearch, 31S-005-008) in PBS 0.02% Tween, followed by rotation at room temperature for 30 min and washed three times with PBS 0.02% Tween. Then beads were re-suspended in PBS 0.02% Tween and 7.5 μL of mouse monoclonal anti-LUCA15 (200 μg/mL, sc-515419, Santa Cruz) and incubated on a rotator at 4 °C. For the non-specific (IgG) control, beads were prepared as for AbM but without the addition of the mouse monoclonal anti-LUCA15 antibody. The day after, both beads were washed three times with ice-cold 1X PXL buffer prior to the addition of the mouse brain lysates. A treatment was performed with addition of 10 μL of a 1:10 dilution of stock solution (Affymetrix, P/N:70194Y). Based on phosphoimaging results, membrane pieces containing RNA-RBM5 complexes around 130 KDa (Supplementary Fig. 6) were cut for each sample and RNA isolated for multiplex library preparation as described previously[101]. A total of 18 libraries was generated, pooled and sequenced on an Illumina HiSeq sequencer aiming for a total depth of 30 million single end reads (1×150 bp). Sequencing reads were processed (Trimmomatic: standard parameters[102]), mapped to the mm10 mouse reference genome using bowtie and PCR duplicates collapsed using tools developed in-house or found in galaxy[99]. Mapped reads were then clustered, followed by quantification of the number of reads for each region for each sample. Clusters were then annotated, and their size normalized to the sample size before subsequent analyses. Clusters with a two-fold enrichment in both AbR and AbM samples compared to IgG samples were included in the list of RBM5-binding sites. Differences in RBM5 binding to AbR and AbM samples compared to IgG samples were included in subsequent analyses. Clusters with a two-fold enrichment in both AbR and AbM samples compared to IgG samples were included in the list of RBM5-binding sites. Differences in RBM5 binding to transcripts were also defined by an at least two-fold change in reads over the binding sites between HD and WT samples with both antibodies. Significance of overlaps was assessed by Fisher’s exact test.

RNA-seq analysis
Mouse brain tissue from the same animals as for the RBM5-CLIP analysis was used for RNA-seq analysis. Total RNA was extracted from a small fraction of each of the non-cross linked brain halves using the RNeasy micro kit (Qiagen). Sequencing libraries were constructed from 200 ng of total RNA using NEBNext rRNA Depletion Kit (Human/Mouse/Rat), stranded NEBNext Ultra II Directional RNA Library Prep kit for Illumina and NEBNext Multiplex Oligos for Illumina (NEB). Libraries were sequenced on a NextSeq500 Illumina aiming for a depth of 10 million paired end reads (2×75 bp) per sample. Sequencing reads were trimmed to remove poor quality sequence and adaptors using Trimmomatic[102] using parameters LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:33. Sequence reads were mapped to the mm10 mouse reference genome using RNA STAR (v2.7.3) following the two-pass alignment protocol[103]. BAM files were imported in SeqMonk (v 1.45.4, Babraham Institute) where data was assessed for data integrity (RNA-Seq QC pipeline), and quantified using the RNA-Seq quantitation pipeline to generate raw counts to mRNA and setting library type to ‘opposing strand specific’. Differentially expressed genes were calculated using SeqMonk edgeR via the ‘statistical test on replicated data’ script as generated via SeqMonk. For identification of differentially expressed exons and introns we quantified reads over each exon and intron in SeqMonk and then performed edgeR analysis. Transcripts that had changes in 100% of their exons or introns were excluded from further analysis as this indicated a differential expression of the whole transcript.

RNA isolation, cDNA library preparation and RT-PCR
For PCR validation of alternative splicing, WT and R6/2 HD brains were collected from animals, independent from the ones used for RBM5-CLIP and RNA-Seq. In this case, brain halves were not dissociated as described before but immediately snap-frozen. Total RNA was then extracted with Trizol and RNA clean and concentrator-25 kit (Zymo), where a separate brain was used for each replicate. Single-strand cDNA was synthesized using 1 μg total RNA and the Superscript III First-Strand Synthesis Supermix. PCR was performed from 1:10 cDNA dilution with Q5 Hot Start High-Fidelity 2X Master Mix (NEB) and the oligonucleotides (0.2 μM) described below. PCR conditions were similar for all sets of oligonucleotides: 2 min 98 °C, 30× (30 s 98 °C, 30 s 60 °C, 1 min 72 °C), 5 min 72 °C. Samples from different animals were processed in parallel from RNA extraction to PCR. Similar volumes of PCR reactions for each sample were loaded and run in parallel on TAE 2% agarose gels with gel red (Biotum) and 100 bp marker (NEB) before imaging with UV imager (Biorad).

The following oligonucleotide forward (fw) and reverse (rev) primer pairs were used for RT-PCR of selected candidates (see also Fig. 5): Adams10 (fw: CTACCTCGCTTCACAGAGGA; rev: CCACCGCATCTGGATTCA); Atrx (fw: GAGACCAAGACCCGTATTG; rev: GGGCGAGAACATCATCCAGGA; Ptpnm (fw: TTCCTACCCCTGTGACCTCG; rev: ATCCGTGTCATCAATACTATT).

Abundance of the PCR products were quantified using the gel analysis pipeline in Imagel (https://imagej.nih.gov/) on colour-reversed gel pictures taken after short exposure, whereas the images shown in figures were taken after longer exposure. Significance of differences between the PCR products from WT and HD samples was assessed using a standard two-tailed test in Prism assuming equal variance. The average mean and standard deviation (error bars) for band intensities for each genotype can be seen on the graph and in the Source Data file. Significance threshold for p values was set to 0.05. p Values for the comparisons (HD vs WT) are as follows: Atrx band 1 p = 0.0101, band 2 p = 0.371; Ptpnm band 1 p = 0.024, band 2 p = 0.856; Clasrp band 1 p = 0.001, band 2 p = 0.063; Adams10 band 1 p = 0.016, band 2 p = 0.239, band 3 p = 0.056, band p = 0.632.

Overexpression and knock-down of RBM5 in human LGE-patterned neurons
hESC (RC17 from Roslin Cells, hPSCreg Rce021-A) were maintained in Laminin-521 (1 μg/cm², Biolamina, #LN521-02) diluted in PBS+/+ (ThermoFisher, #14040091) and passaged at described previously[100]. Differentiation towards LGE-patterned neurons was carried out using a modified version of a previously published protocol[101]. More precisely, 1 day of differentiation 0, 70–90% confluent hESC were dissociated using 0.5 mM EDTA (Thermo Fisher Scientific, #15575020) for 7 min at 37 °C. Then, cells were collected and resuspended to a single-cell suspension in wash medium containing 9.5 mL DMEM/F12 (ThermoFisher, #10565018) and 0.5 mL KnockOut Serum Replacement (ThermoFisher, #10828028) and counted using a Neubauer counting chamber. For neural induction, hESC were plated on Laminin-111 coated plates (2 μg/cm², Biolamina, #LN111-02) at a density of 25,000 cells/cm² in N2 medium supplemented with 10 μM SB413542 (Milenyi, #130-106-543) and 100 ng/mL Noggin (Milenyi, #130-103-456) from day 0 to day 9. 10 μM Y-27632 (ROCK inhibitor, Miltenyi, #130-106-536) was added to the media for the first 48 h to increase survival. N2 medium was changed every two days until day 9 of differentiation. At day 9, media was...
replaced with N2 medium plus Activin A (25 ng/mL, R&D Systems, #338-AC-010).

At day 11, early neural progenitors were dissociated in 75 μL/cm² acutacue (ThermoFisher, #A1105-01) for 7 min at 37 °C collected and resuspended to a single-cell suspension in wash medium and counted as previously described. Cells were replated at a cell density of 800,000 cells/cm² in Lammini-n-1 (2 μg/cm², Biolamina, #LNN1-02) coated cell culture plates in B27 media supplemented with 0.2 mM ascorbic acid (Sigma-Merck, #A4403-100MG), 20 μg/mL BDNF (Milteny, #130-096-286) and Activin A (25 ng/mL, R&D Systems, #338-AC-010), adding Y-27632 for 24 h. Media was changed every second day until day 16.

At day 16, progenitors were dissociated in acutacue and counted as described before. Progenitors were transduced with custom made lentiviral (LV) particles containing either knock-down and over-expression vectors for RBMS and their respective controls (Vector-Buil Inc, Catalogue #: LVM(VB010000-0009mxc)-C) and subsequently stored at -80 °C. Significance of differences between the PCR products from WT and HD samples was assessed using a standard two-tailed t-test assuming equal variance. The average mean and standard deviation (error bars) for band intensities for each genotype can be seen on the graph and are provided in the Source Data file. Significance threshold for p was set to 0.05. p Values for the comparison of control OE and RBMS OE are the following: RBMS−0.0203; ATRX−0.0426; ADAMTS10−0.0049; PTRPN−0.2474, p Values for the comparison of control OE and RBMS OE are the following: RBMS−0.0011; ATRX−0.0313; ADAMTS10−0.0549; PTRPN−0.0363.

RBMS AP-MS from WT and HD R6/2 transgenic mouse brain tissue
In all, 25 μL of protein-G Dynabeads (10003D; Thermo Fischer) were washed three times with PBS and after re-suspension in PBS, 20 μL of polyclonal rabbit antibody (HPA01S011; Merck/Sigma), 10 μL of mouse monoclonal anti-LC15 antibody (200 μg/mL; sc-51419, Santa Cruz) or no antibody (negative control) was added and incubated overnight on a rotator at 4 °C. Beads were washed three times with PBS and the antibodies were cross-linked to the protein-G beads by incubation in 19 mM Dithimyl pimelimidide dihydrochloride (D8388, Sigma Aldrich) in 20 mM sodium borate (pH 9.0) for 30 min at room temperature on a rotator. Beads were washed three times with ice-cold PBS and non-cross-linked antibodies eluded with 0.5 M glycine (pH 2.5) on a rotator for 10 min. Beads were washed three times with PBS and three times in lysis buffer prior to addition to brain tissue lysates. Homogenized WT and HD mouse half-brains (homogenized as for pCLAP) were re-suspended in lysis buffer (50 mM TrisHCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 0.1% Na-deoxycholate, 5 mM Glycerol, 1 mM, 5 mM β-glycerophosphate, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 125 U/mL of Benzonase (E1014, Sigma Aldrich) and 1 tablet per 10 mL of Complete mini EDTA-free protease inhibitor cocktail (469316001; Roche) and lysed for 1 h on a rotator at 4 °C and spun down at 4700 x g for 15 min at 4 °C. Protein concentration was measured by Bradford assay using Quick Start Bradford 1× Dye Reagent (#5000205; Bio-Rad) and lysate containing 2 mg of protein was used for each Co-IP replicate. Samples were pre-cleared by incubation with protein-G-dynabeads for 1 h at 4 °C on a rotator and the supernatant was incubated with the beads-cross-linked to AbM, AbR or no antibody for 4 h on a rotator at 4 °C. The Co-IP samples were washed three times with lysis buffer without benzonase or protease inhibitors three times for 10 min on a rotator at 4 °C. Samples were washed with PBS three times to remove detergent and salts and re-suspended in digestion buffer (50 mM ABC (pH 8.0), 10 mM CAA, 5 mM TCEp). 2.5 μL of trypsin (0.5 μg/μL; Sigma) and LysC (0.5 μg/μL; Wako) was added to each sample and incubated for 1 h at 4 °C on a shaker at 1200 rpm, followed by overnight incubation at 37 °C on a shaker at 350 rpm. The supernatant with the digested peptides was moved to a new tube, acidified, desalted and concentrated on C18 StageTips as described for the pCLAP experiments.

Samples were eluded from StageTips in 2 steps with 40% ACN and 0.1% acetic acid, concentrated and acetonitrile was evaporated using a Vacufuge at 45 °C until the acetonitrile had evaporated and 5% ACN and 0.1% TFA was added to each sample to bring sample volume to 30 μL. 1/6 of each sample was separated on an EASY-nLC 1200 System (Thermo Fischer) with 15 cm long in-house pulled and packed column,
filled with ReproSil-Pur 120 C18-AQ, 1.9 µm (r119.aq; Dr. Maisch). Peptides were separated on a 80 min low pH gradient with a mobile phase of 0.1% Formic acid (1.00264.1000, WVR) and an Acetonitrile concentration gradient ranging from 0 to 80%. From the tip of the column, samples were ionized at 270 °C and 2 kV and analysed on an Orbitrap Exploris 480 Mass Spectrometer (Thermo Fischer). The full scan was done in positive mode with Orbitrap resolution of 120,000, scan range 300–1750, AGC target Custom, normalized AGC target 200%. For each full scan 9 fragment scans were selected, with an intensity threshold of 2.5E + 5, included charge states 2–6, dynamic exclusion of 60 s and a mass tolerance of 20 ppm. Fragment scans were done with an isolation window of 1.3 m/z, Orbitrap resolution of 45,000, HCD collision energy of 25%, AGC target custom, normalized AGC target 200% and maximum injection time mode auto. Analysis of the MS data was done as described for the pCLAP samples, with the difference that ‘match between runs’ was turned off.

**Gene Ontology (GO) term analysis of CLIP, RNA-seq and Co-IP samples**

GO term analysis in this study was done using GeneCodis (https://genecodis.genyco.es/) and PANTHER⁴⁰. The only exception is the RBMS proteins interactome study, where AmiGO (http://geneontology.org/) and PANTHER⁴⁰ were used, since GeneCodis was unavailable at that point in time. All shown p values are using the multiple hypothesis corrected values provided by these tools.

**Reporting summary**

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

**Data availability**

The mass spectrometry proteomics data generated in this study have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD029227. CLIP-seq and RNA-seq data can be accessed via the following GEO accession number: GSE187445. Source data are provided with this paper.

**References**

41. Jin, W., Niu, Z., Xu, D. & Li, X. RBM5 promotes exon 4 skipping of AID pre-mRNA by competing with the binding of U2AF65 to the poly-pyrimidine tract. FEBS Lett. 596, 3852–3857 (2012).


Acknowledgements

The work carried out in this study was in part supported by the Novo Nordisk Foundation Center for Protein Research, the Novo Nordisk Foundation (NNF14CC0001, NNF13OC0006477, M.L.N.; NNF21CC0073729, A.A.-M. and A.K.; Distinguished Investigator Grant NNF19OC0054518, J.B.), The Danish Council of Independent Research (8020-00220B, M.L.N.), The Danish Cancer Society (R146-A9159-16-S2, M.L.N.), the Lundbeck Foundation (R336-2020-963, A.A.-M. and A.K.; R370-2021-866, N.F.), Starting Grant from the European Research Council (ERC) (802899, T.K.H.S.) and Department of Infectious Diseases, Hvidovre Hospital. The proteomics technology applied were part of a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement EPIC-XS-823839 (M.L.N.). Department of Clinical Microbiology, Hvidovre Hospital, kindly made miSeq and NextSeq sequencing platforms available. We would like to thank members of the NNF-CPR Mass Spectrometry Platform for instrument support and technical assistance. The research was supported by Stadsåbne Svend Ahrend Larsen og Grosseer Jon Johanne- sons Fond. We thank Associate Professor Anne Næremølle and Rabab Nima at Department of Cellular and Molecular Medicine and Bente Langeland Kristensen at the Department of Experimental Medicine, Faculty of Health and Medical Sciences, University of Copenhagen for help with the R6/2 mouse planning, breeding, caretaking, and genotyping.

Author contributions

The initial idea of the project was devised by M.M., N.H.S. and M.L.N. M.M., N.F., M.L.N., N.H.S., A.A.-M., T.K.H.S. and A.K. all contributed to study design and experimental design at different steps. Experimental work was conducted by M.M. (all experiments, except RT-PCR and neuron work), N.F. (CLIP-seq analysis, RNA-seq and RT-PCR) and N.H.S. (Mouse work, brain collection and cell separation of brain samples) and A.A.M. (Neuronal differentiation, lentivirus transduction, RT-qPCR). All data analysis was done by M.M., N.F. and D.T.H. Resources and funding were provided by M.L.N., T.K.H.S., J.B., A.K., A.A.-M. and N.F. The original draft of the manuscript was written by M.M. and all other authors critically revised the manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-023-39936-x.

Correspondence and requests for materials should be addressed to Meeli Mullari or Michael L. Nielsen.

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023